Primecap Management Co. CA cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 9.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 294,989 shares of the medical research company's stock after selling 30,967 shares during the period. Primecap Management Co. CA owned approximately 0.16% of IQVIA worth $57,968,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Smith Group Asset Management LLC bought a new position in IQVIA during the fourth quarter worth about $1,616,000. Nordea Investment Management AB raised its stake in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after purchasing an additional 452,029 shares during the period. Hickory Asset Management Inc. acquired a new stake in shares of IQVIA in the 4th quarter valued at about $941,000. Fifth Third Bancorp raised its stake in shares of IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock valued at $2,590,000 after purchasing an additional 1,521 shares during the period. Finally, Graphene Investments SAS raised its stake in shares of IQVIA by 22.0% in the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock valued at $2,948,000 after purchasing an additional 2,700 shares during the period. 89.62% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several analysts have issued reports on the company. William Blair reissued an "outperform" rating on shares of IQVIA in a research note on Wednesday, December 11th. Stifel Nicolaus dropped their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Robert W. Baird dropped their price target on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 21st. Finally, Morgan Stanley lifted their target price on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $249.05.
Check Out Our Latest Stock Report on IQVIA
IQVIA Stock Performance
NYSE IQV traded up $1.59 during trading on Friday, reaching $185.85. 3,242,588 shares of the company's stock were exchanged, compared to its average volume of 1,237,438. The business has a 50 day moving average price of $194.94 and a 200-day moving average price of $208.73. The stock has a market capitalization of $32.77 billion, a P/E ratio of 24.78, a PEG ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $254.80.
IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
